Telix Pharmaceuticals Limited announced that it has entered into a co-promotion agreement Eckert & Ziegler Strahlen und Medizintechnik AG (EZAG) for the combination of EZAG's GalliaPharm® (gallium-68 generator) and Telix's investigational prostate cancer imaging product Illuccix® (Kit for the preparation of 68Ga-PSMA-11 injection). Under the terms of the agreement, Telix and EZAG will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will co-promote Illuccix® and GalliaPharm® to ensure healthcare providers nationwide have secure access to Illuccix® and Ga-68 generators.

Illuccix® may be prepared using a gallium-68 generator and has been validated for use with the GalliaPharm® generator. The Illuccix® New Drug Application (NDA) is currently under review by the United States Food and Drug Administration (FDA) and includes support for GalliaPharm®.